Cargando…

Co-Amorphous Versus Deep Eutectic Solvents Formulations for Transdermal Administration

Transdermal administration can be considered as an interesting route to overcome the side-effects inherent to oral intake. Designing topical formulations with maximum drug efficiency requires the optimization of the permeation and the stability of the drug. The present study focuses on the physical...

Descripción completa

Detalles Bibliográficos
Autores principales: Guinet, Yannick, Paccou, Laurent, Hédoux, Alain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10303655/
https://www.ncbi.nlm.nih.gov/pubmed/37376158
http://dx.doi.org/10.3390/pharmaceutics15061710
_version_ 1785065327922511872
author Guinet, Yannick
Paccou, Laurent
Hédoux, Alain
author_facet Guinet, Yannick
Paccou, Laurent
Hédoux, Alain
author_sort Guinet, Yannick
collection PubMed
description Transdermal administration can be considered as an interesting route to overcome the side-effects inherent to oral intake. Designing topical formulations with maximum drug efficiency requires the optimization of the permeation and the stability of the drug. The present study focuses on the physical stability of amorphous drugs within the formulation. Ibuprofen is commonly used in topical formulations and then was selected as a model drug. Additionally, its low Tg allows easy, unexpected recrystallization at room temperature with negative consequence on skin penetration. In this study, the physical stability of amorphous ibuprofen was investigated in two types of formulations: (i) in terpenes-based deep eutectic solvents (DES) and (ii) in arginine-based co-amorphous blends. The phase diagram of ibuprofen:L-menthol was mainly analyzed by low-frequency Raman spectroscopy, leading to the evidence of ibuprofen recrystallization in a wide range of ibuprofen concentration. By contrast, it was shown that amorphous ibuprofen is stabilized when dissolved in thymol:menthol DES. Forming co-amorphous arginine–ibuprofen blends by melting is another route for stabilizing amorphous ibuprofen, while recrystallization was detected in the same co-amorphous mixtures obtained by cryo-milling. The mechanism of stabilization is discussed from determining T(g) and analyzing H-bonding interactions by Raman investigations in the C=O and O–H stretching regions. It was found that recrystallization of ibuprofen was inhibited by the inability to form dimers inherent to the preferential formation of heteromolecular H-bonding, regardless of the glass transition temperatures of the various mixtures. This result should be important for predicting ibuprofen stability within other types of topical formulations.
format Online
Article
Text
id pubmed-10303655
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103036552023-06-29 Co-Amorphous Versus Deep Eutectic Solvents Formulations for Transdermal Administration Guinet, Yannick Paccou, Laurent Hédoux, Alain Pharmaceutics Article Transdermal administration can be considered as an interesting route to overcome the side-effects inherent to oral intake. Designing topical formulations with maximum drug efficiency requires the optimization of the permeation and the stability of the drug. The present study focuses on the physical stability of amorphous drugs within the formulation. Ibuprofen is commonly used in topical formulations and then was selected as a model drug. Additionally, its low Tg allows easy, unexpected recrystallization at room temperature with negative consequence on skin penetration. In this study, the physical stability of amorphous ibuprofen was investigated in two types of formulations: (i) in terpenes-based deep eutectic solvents (DES) and (ii) in arginine-based co-amorphous blends. The phase diagram of ibuprofen:L-menthol was mainly analyzed by low-frequency Raman spectroscopy, leading to the evidence of ibuprofen recrystallization in a wide range of ibuprofen concentration. By contrast, it was shown that amorphous ibuprofen is stabilized when dissolved in thymol:menthol DES. Forming co-amorphous arginine–ibuprofen blends by melting is another route for stabilizing amorphous ibuprofen, while recrystallization was detected in the same co-amorphous mixtures obtained by cryo-milling. The mechanism of stabilization is discussed from determining T(g) and analyzing H-bonding interactions by Raman investigations in the C=O and O–H stretching regions. It was found that recrystallization of ibuprofen was inhibited by the inability to form dimers inherent to the preferential formation of heteromolecular H-bonding, regardless of the glass transition temperatures of the various mixtures. This result should be important for predicting ibuprofen stability within other types of topical formulations. MDPI 2023-06-12 /pmc/articles/PMC10303655/ /pubmed/37376158 http://dx.doi.org/10.3390/pharmaceutics15061710 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Guinet, Yannick
Paccou, Laurent
Hédoux, Alain
Co-Amorphous Versus Deep Eutectic Solvents Formulations for Transdermal Administration
title Co-Amorphous Versus Deep Eutectic Solvents Formulations for Transdermal Administration
title_full Co-Amorphous Versus Deep Eutectic Solvents Formulations for Transdermal Administration
title_fullStr Co-Amorphous Versus Deep Eutectic Solvents Formulations for Transdermal Administration
title_full_unstemmed Co-Amorphous Versus Deep Eutectic Solvents Formulations for Transdermal Administration
title_short Co-Amorphous Versus Deep Eutectic Solvents Formulations for Transdermal Administration
title_sort co-amorphous versus deep eutectic solvents formulations for transdermal administration
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10303655/
https://www.ncbi.nlm.nih.gov/pubmed/37376158
http://dx.doi.org/10.3390/pharmaceutics15061710
work_keys_str_mv AT guinetyannick coamorphousversusdeepeutecticsolventsformulationsfortransdermaladministration
AT paccoulaurent coamorphousversusdeepeutecticsolventsformulationsfortransdermaladministration
AT hedouxalain coamorphousversusdeepeutecticsolventsformulationsfortransdermaladministration